Colon-targeted engineered postbiotics nanoparticles alleviate osteoporosis through the gut-bone axis

Area of Science:

• Gastroenterology
• Orthopedics
• Nanotechnology
• Immunology

Background:

• Intestinal inflammation impacts bone health via the gut-bone axis.
• Current postbiotic supplements for osteoporosis lack optimal efficacy and safety.
• Targeted delivery systems are needed to enhance therapeutic effects.

Purpose of the Study:

• To develop a colon-targeted nanoparticle system for sustained release of butyric acid.
• To investigate the therapeutic potential of engineered postbiotics nanoparticles on inflammation-related bone loss.
• To evaluate the efficacy of this strategy in mitigating osteoporosis and preventing fractures.

Main Methods:

• Surface engineering of polyvinyl butyrate nanoparticles with shellac resin for colon targeting.
• Utilizing engineered nanoparticles for sustained release of butyric acid in the colorectal region.
• Assessing nanoparticle effects on macrophage activation, redox balance, gut microbiota, and epithelial barrier function.
• Evaluating the impact on osteoblast/osteoclast activity and bone properties in disease models.

Main Results:

• Engineered nanoparticles successfully delivered butyric acid to the colon, suppressing inflammation.
• Treatment modulated gut microbiota, restored epithelial integrity, and reduced pro-inflammatory responses.
• Systemic inflammation remission led to balanced osteoblast and osteoclast activity.
• Bone quality, quantity, and mechanical properties were improved, indicating fracture prevention potential.

Conclusions:

• Colon-targeted engineered postbiotics nanoparticles offer a promising therapeutic strategy for osteoporosis.
• This approach effectively targets the gut-bone axis to combat inflammation-related bone loss.
• The developed system demonstrates potential for safe and effective fracture prevention.